AbbVie (NYSE:ABBV) Announces Earnings Results

AbbVie (NYSE:ABBV) issued its quarterly earnings results on Friday. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04, FiscalAI reports. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the firm earned $2.97 EPS. The business’s revenue was up 10.2% on a year-over-year basis. AbbVie updated its Q3 2026 guidance to 3.840-3.880 EPS.

Here are the key takeaways from AbbVie’s conference call:

• Strong second-quarter execution lifted revenue 10.2% to nearly $17 billion and adjusted EPS to $3.65, beating expectations. AbbVie raised full-year revenue guidance by $300 million to approximately $67.6 billion and increased adjusted EPS guidance to $13.87–$14.07.
• Immunology and neuroscience remained key growth engines, led by SKYRIZI sales of $5.5 billion, up 24%, and RINVOQ sales above $2.5 billion, up 23.7%; neuroscience revenue grew about 20%. Management expects further SKYRIZI momentum from a potential U.S. approval of subcutaneous Crohn’s induction dosing later this year.
• AbbVie highlighted multiple pipeline and business-development catalysts, including the planned Apogee acquisition, European approvals for RINVOQ in vitiligo and alopecia areata, expected U.S. approval decisions for tavapadone, and progress across oncology ADCs and immunology combinations.
• The Apogee transaction is expected to close in the third quarter and will dilute 2026 EPS by an estimated $0.14, while increasing R&D spending and interest expense. AbbVie plans to use interim financing and issue long-term debt, targeting a return to two-times net leverage within two to three years.
• Oncology revenue declined 2.4% operationally, primarily due to expected IMBRUVICA pressure from IRA pricing and competition, while aesthetics revenue fell 0.9% as JUVÉDERM sales declined 6.6%. HUMIRA sales also fell 36.1% because of biosimilar competition.

AbbVie Stock Down 2.4%

AbbVie stock opened at $251.33 on Friday. The stock has a market cap of $444.05 billion, a price-to-earnings ratio of 71.00, a P/E/G ratio of 0.83 and a beta of 0.30. AbbVie has a 12-month low of $187.62 and a 12-month high of $267.47. The business’s 50-day simple moving average is $239.10 and its 200 day simple moving average is $224.05.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently made changes to their positions in ABBV. Bank of Jackson Hole Trust increased its holdings in AbbVie by 0.6% in the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares during the last quarter. Imprint Wealth LLC grew its holdings in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the period. one8zero8 LLC increased its stake in AbbVie by 0.5% in the fourth quarter. one8zero8 LLC now owns 9,825 shares of the company’s stock valued at $2,245,000 after purchasing an additional 50 shares in the last quarter. Papamarkou Wellner Asset Management inc. boosted its position in shares of AbbVie by 0.5% during the fourth quarter. Papamarkou Wellner Asset Management inc. now owns 9,611 shares of the company’s stock worth $2,196,000 after purchasing an additional 52 shares in the last quarter. Finally, Twin Focus Capital Partners LLC increased its position in shares of AbbVie by 5.6% in the 4th quarter. Twin Focus Capital Partners LLC now owns 1,082 shares of the company’s stock valued at $247,000 after buying an additional 57 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research reports. Wells Fargo & Company boosted their price target on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. Bank of America lifted their price target on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Finally, Morgan Stanley boosted their price target on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $269.29.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.